Some researchers believe DMT, a powerful psychedelic that may naturally occur in the brain, could be your soul’s “ferryman.” ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of GH Research (NasdaqGM:GHRS) with a Buy recommendation ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief ...

GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel ...

See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed ...

GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel and proprietary mebufotenin (5-MeO-DMT) therapies for conditions like ...

We offer clinical studies with experienced therapists utilizing diverse molecules including LSD, MDMA, Methylone, psilocybin, and 5-MeO- DMT. Conditions treated are anxiety, adjustment disorder ...

or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.